These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22832252)

  • 1. MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine.
    Singh M; Kazzaz J; Ugozzoli M; Baudner B; Pizza M; Giuliani M; Hawkins LD; Otten G; O'Hagan DT
    Hum Vaccin Immunother; 2012 Apr; 8(4):486-90. PubMed ID: 22832252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).
    Baudner BC; Ronconi V; Casini D; Tortoli M; Kazzaz J; Singh M; Hawkins LD; Wack A; O'Hagan DT
    Pharm Res; 2009 Jun; 26(6):1477-85. PubMed ID: 19255727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.
    O'Hagan DT; Ugozzoli M; Barackman J; Singh M; Kazzaz J; Higgins K; Vancott TC; Ott G
    Vaccine; 2000 Mar; 18(17):1793-801. PubMed ID: 10699327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
    Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
    FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and preclinical characterization of a novel vaccine adjuvant formulation consisting of a synthetic TLR4 agonist in a thermoreversible squalene emulsion.
    Haensler J; Probeck P; Su J; Piras F; Dalençon F; Cotte JF; Chambon V; Iqbal SM; Hawkins L; Burdin N
    Int J Pharm; 2015; 486(1-2):99-111. PubMed ID: 25794609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88.
    Seubert A; Calabro S; Santini L; Galli B; Genovese A; Valentini S; Aprea S; Colaprico A; D'Oro U; Giuliani MM; Pallaoro M; Pizza M; O'Hagan DT; Wack A; Rappuoli R; De Gregorio E
    Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11169-74. PubMed ID: 21690334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of adjuvants to improve immune responses against TdaP vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid A.
    Agnolon V; Bruno C; Leuzzi R; Galletti B; D'Oro U; Pizza M; Seubert A; O'Hagan DT; Baudner BC
    Int J Pharm; 2015 Aug; 492(1-2):169-76. PubMed ID: 26149936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome.
    Morefield GL; Hawkins LD; Ishizaka ST; Kissner TL; Ulrich RG
    Clin Vaccine Immunol; 2007 Nov; 14(11):1499-504. PubMed ID: 17715328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.
    Desbien AL; Reed SJ; Bailor HR; Dubois Cauwelaert N; Laurance JD; Orr MT; Fox CB; Carter D; Reed SG; Duthie MS
    Eur J Immunol; 2015 Feb; 45(2):407-17. PubMed ID: 25367751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MF59 adjuvant: the best insurance against influenza strain diversity.
    O'Hagan DT; Rappuoli R; De Gregorio E; Tsai T; Del Giudice G
    Expert Rev Vaccines; 2011 Apr; 10(4):447-62. PubMed ID: 21506643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.
    Podda A; Del Giudice G
    Expert Rev Vaccines; 2003 Apr; 2(2):197-203. PubMed ID: 12899571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders.
    Robinson C; Baehr C; Schmiel SE; Accetturo C; Mueller DL; Pravetoni M
    Hum Vaccin Immunother; 2019; 15(4):909-917. PubMed ID: 30625019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates.
    Traquina P; Morandi M; Contorni M; Van Nest G
    J Infect Dis; 1996 Dec; 174(6):1168-75. PubMed ID: 8940205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants.
    Valensi JP; Carlson JR; Van Nest GA
    J Immunol; 1994 Nov; 153(9):4029-39. PubMed ID: 7930610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
    J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
    Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
    Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
    Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.
    Yang M; Yan Y; Fang M; Wan M; Wu X; Zhang X; Zhao T; Wei H; Song D; Wang L; Yu Y
    Int Immunopharmacol; 2012 Aug; 13(4):408-16. PubMed ID: 22595192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.
    Pass RF
    J Clin Virol; 2009 Dec; 46 Suppl 4(Suppl 4):S73-6. PubMed ID: 19647480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.